<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320553</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_11_02</org_study_id>
    <nct_id>NCT01320553</nct_id>
  </id_info>
  <brief_title>Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis</brief_title>
  <official_title>Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will test if administration of different concentrations of 1334H eyedrops
      will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or
      older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post-challenge (0-4 scale, allowing half unit increments with 0 representing none and 4 representing Incapacitating itch with an irresistible urge to rub) at Visit 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness Evaluated by the Investigator</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Ciliary redness and episcleral redness were evaluated by the investigator at 7, 15, and 20 minutes post-CAC using a 4-point (0 indicating none and 4 indicating extremely severe i.e. large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) scale with half-unit (1-step) increments allowed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>SPARC1102 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1102 II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPARC1102 III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1102 I</intervention_name>
    <description>SPARC1102 I will be administered in both eyes</description>
    <arm_group_label>SPARC1102 I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1102 II</intervention_name>
    <description>SPARC1102 II will be administered in both eyes</description>
    <arm_group_label>SPARC1102 II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1102 III</intervention_name>
    <description>SPARC1102 III will be administered in both eyes</description>
    <arm_group_label>SPARC1102 III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle will be administered in both eyes</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form and HIPAA document

          -  Willing and able to comply with all study procedures

          -  Be at least 10 years of age at the time of enrollment

          -  LogMar 0.7 or better, in each eye

          -  History of ocular allergies, and a positive skin and ocular allergic reaction to
             allergens

          -  A negative urine pregnancy test if female of childbearing potential and must use
             adequate birth control throughout the study period

        Exclusion Criteria:

          -  have known contraindications or sensitivities to the use of any of the study
             medications(s) or their components;

          -  have any ocular condition that, in the opinion of the investigator, could affect the
             subject's safety or trial parameters (including but not limited to narrow angle
             glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis,
             pterygium or a diagnosis of dry eye);

          -  have a current diagnosis or history of open angle glaucoma or ocular hypertension;

          -  have had ocular surgical intervention within three (3) months prior to Visit 1 or
             during the study and/or a history of refractive surgery within the past 6 months;

          -  have a known history of retinal detachment, diabetic retinopathy, or progressive
             retinal disease;

          -  have the presence of an active ocular infection (bacterial, viral or fungal), positive
             history of an ocular herpetic infection, or preauricular lymphadenopathy at any visit;

          -  manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
             at screening or during study

          -  have used an investigational drug or device within 30 days of the study or be
             concurrently enrolled in another investigational drug or device study within 30 days
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ORA Inc</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2016</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1334 H 0.15%</title>
          <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions
1334 H 0.15%: 1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="P2">
          <title>1334 H-0.3%</title>
          <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
1334 H-0.3%: 1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="P3">
          <title>1334 H-0.45%</title>
          <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
1334 H-0.45%: 1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="P4">
          <title>Vehicle</title>
          <description>Vehicle eye drops (solution)will be administered in both eyes at 3 occasions
Placebo: Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1334 H 0.15%</title>
          <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions
1334 H 0.15%: 1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="B2">
          <title>1334 H-0.3%</title>
          <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
1334 H-0.3%: 1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="B3">
          <title>1334 H-0.45%</title>
          <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
1334 H-0.45%: 1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo eye drops (solution)will be administered in both eyes at 3 occasions
Placebo: Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="11.58"/>
                    <measurement group_id="B2" value="34.8" spread="15.42"/>
                    <measurement group_id="B3" value="33.7" spread="15.94"/>
                    <measurement group_id="B4" value="40.6" spread="13.57"/>
                    <measurement group_id="B5" value="35.6" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching</title>
        <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post-challenge (0-4 scale, allowing half unit increments with 0 representing none and 4 representing Incapacitating itch with an irresistible urge to rub) at Visit 5.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>Of the 122 subjects enrolled in the study, a total of 8 subjects did not complete the study: 1 in the 1334H 0.15% group, 4 in the 1334H 0.3% group, 2 in the 1334H 0.45% group and 1 in the vehicle treated group.
The Per Protocol population, comprised of all subjects who completed the study with no protocol violations, totaled 107 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>1334 H 0.15%</title>
            <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions
1334 H 0.15%: 1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O2">
            <title>1334 H-0.3%</title>
            <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
1334 H-0.3%: 1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O3">
            <title>1334 H-0.45%</title>
            <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
1334 H-0.45%: 1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle eye drops (solution)will be administered in both eyes at 3 occasions
Placebo: Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Ocular itching evaluated by the subject at 3, 5, and 7 minutes post-challenge (0-4 scale, allowing half unit increments with 0 representing none and 4 representing Incapacitating itch with an irresistible urge to rub) at Visit 5.</description>
          <population>Of the 122 subjects enrolled in the study, a total of 8 subjects did not complete the study: 1 in the 1334H 0.15% group, 4 in the 1334H 0.3% group, 2 in the 1334H 0.45% group and 1 in the vehicle treated group.
The Per Protocol population, comprised of all subjects who completed the study with no protocol violations, totaled 107 subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.085"/>
                    <measurement group_id="O2" value="1.57" spread="1.174"/>
                    <measurement group_id="O3" value="1.16" spread="1.125"/>
                    <measurement group_id="O4" value="1.88" spread="0.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.068"/>
                    <measurement group_id="O2" value="1.40" spread="1.108"/>
                    <measurement group_id="O3" value="1.23" spread="1.109"/>
                    <measurement group_id="O4" value="2.12" spread="0.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.989"/>
                    <measurement group_id="O2" value="1.01" spread="0.931"/>
                    <measurement group_id="O3" value="0.86" spread="0.889"/>
                    <measurement group_id="O4" value="2.06" spread="0.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness Evaluated by the Investigator</title>
        <description>Ciliary redness and episcleral redness were evaluated by the investigator at 7, 15, and 20 minutes post-CAC using a 4-point (0 indicating none and 4 indicating extremely severe i.e. large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) scale with half-unit (1-step) increments allowed.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1334 H 0.15%</title>
            <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions
1334 H 0.15%: 1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O2">
            <title>1334 H-0.3%</title>
            <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
1334 H-0.3%: 1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O3">
            <title>1334 H-0.45%</title>
            <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
1334 H-0.45%: 1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle eye drops (solution)will be administered in both eyes at 3 occasions
Placebo: Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness Evaluated by the Investigator</title>
          <description>Ciliary redness and episcleral redness were evaluated by the investigator at 7, 15, and 20 minutes post-CAC using a 4-point (0 indicating none and 4 indicating extremely severe i.e. large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) scale with half-unit (1-step) increments allowed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.504"/>
                    <measurement group_id="O2" value="1.05" spread="0.700"/>
                    <measurement group_id="O3" value="0.88" spread="0.553"/>
                    <measurement group_id="O4" value="1.04" spread="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.433"/>
                    <measurement group_id="O2" value="0.99" spread="0.740"/>
                    <measurement group_id="O3" value="0.73" spread="0.472"/>
                    <measurement group_id="O4" value="0.92" spread="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.344"/>
                    <measurement group_id="O2" value="0.64" spread="0.609"/>
                    <measurement group_id="O3" value="0.50" spread="0.275"/>
                    <measurement group_id="O4" value="0.62" spread="0.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1334 H 0.15%</title>
          <description>1334H 0.15% eye drops will be administered in both eyes at 3 occasions
1334 H 0.15%: 1334H 0.15% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="E2">
          <title>1334 H-0.3%</title>
          <description>1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
1334 H-0.3%: 1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="E3">
          <title>1334 H-0.45%</title>
          <description>1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
1334 H-0.45%: 1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
        <group group_id="E4">
          <title>Vehicle</title>
          <description>Vehicle eye drops (solution)will be administered in both eyes at 3 occasions
Placebo: Placebo eye drops (solution)will be administered in both eyes at 3 occasions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>anterior chamber cell</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anterior Chamber Pigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Corneal opacity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eyelid Exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eyelid Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Corneal Abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Of the total of 122 subjects, 8 subjects did not complete the study: 114 subjects completed the study, PP population, comprised of all subjects who completed the study with no protocol violations, totaled 107 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shravanti Bhowmik, MD</name_or_title>
      <organization>SPARC</organization>
      <email>shravanti.bhowmik@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

